Detail
Experiment ID:
EXP00100
Reference:
- Title: microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma.
- Author: Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, Smith R, Leeson B, Beard R, Lamb JR, Lim L, Mao M, Dai H, Luk JM
- Journal: Molecular systems biology.2010 Aug 24;6:402.doi:10.1038/msb.2010.58.
- Abstract: Tumorigenesis involves multistep genetic alterations. To elucidate the microRNA (miRNA)-gene interaction network in carcinogenesis, we examined their genome-wide expression profiles in 96 pairs of tumor/non-tumor tissues from hepatocellular carcinoma (HCC). Comprehensive analysis of the coordinate expression of miRNAs and mRNAs reveals that miR-122 is under-expressed in HCC and that increased expression of miR-122 seed-matched genes leads to a loss of mitochondrial metabolic function. Furthermore, the miR-122 secondary targets, which decrease in expression, are good prognostic markers for HCC. Transcriptome profiling data from additional 180 HCC and 40 liver cirrhotic patients in the same cohort were used to confirm the anti-correlation of miR-122 primary and secondary target gene sets. The HCC findings can be recapitulated in mouse liver by silencing miR-122 with antagomir treatment followed by gene-expression microarray analysis. In vitro miR-122 data further provided a direct link between induction of miR-122-controlled genes and impairment of mitochondrial metabolism. In conclusion, miR-122 regulates mitochondrial metabolism and its loss may be detrimental to sustaining critical liver function and contribute to morbidity and mortality of liver cancer patients.
- PMID: 20739924
Expression Profile:
- Description:miR-122 as a Regulator of Mitochondrial Metabolic Gene Network in Hepatocellular Carcinoma
- Organism:Homo sapiens
- Source:GEO
- Source ID:GSE22058
- Platform: GPL10457
- Number of samples:397
- Overall design:Mouse liver profiling: In one treatment regimen, four animals were given four doses of 100mg ASO/kg body weight, administered every other day, and sacrificed one day after the last dose. Four animals treated for four weeks were treated twice weekly with 50mg ASO/kg body weight, and sacrificed two days after the last dose. Mice were sacrificed in the morning, and liver was removed for further analysis. Samples from oligonucleotide-treated mice were referenced against samples from saline-treated mice in fluor-reversed pairs. Human liver profiling: For human HCC patient samples, 192 samples -- 96 resected tumor and 96 adjacent non-tumor liver tissues -- were collected from 96 patients who had undergone hepatectomy for curative treatment of HCC at Queen Mary Hospital, Pokfulam, Hong Kong between 1990 and 2007. Informed consents were obtained from patients regarding the use of the liver specimens for research. Samples were hybridized to Affymetrix arrays for mRNA profiling and were analyzed by quantitative PCR for microRNA profiling.
- Instrument:Rosetta human miRNA qPCR array
Design and Sample:
- Cancer Type:hepatocellular carcinoma
- Cancer SubType:N/A
- Cell Line:N/A
- Experimental Design:cancer vs normal
- Case Sample:hepatocellular carcinoma
- Control Sample:normal liver
- Num of Case:96
- Num of Control:96
- Quantification Software:Limma
- Num of miRNAs:220
Identification:
- Num of Up:83
- Num of Down:63
Time Info:
- Create Time2016-03-14
- Update Time:2021-05-27
Status:
| miRNA ID | Cancer Type | Design | logFC | AveExpr | T value | P value | adj Pvalue | Status | Plot |
|---|